Embla Medical Valuation Multiples

Embla Medical is valued at $1.7B as of October 2026, a 2.2x revenue multiple. In the last 12 months, Embla Medical revenue was $1B and Embla Medical EBITDA was $206M.

Embla Medical Overview

About Embla Medical

Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.


Founded

1971

HQ

Iceland

Employees

4.3K

Financials (LTM)

Revenue: $1B
EBITDA: $206M

EV

$2.2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Embla Medical Financials

Embla Medical reported last 12-month revenue of $1B and EBITDA of $206M.

In the same LTM period, Embla Medical generated $625M in gross profit, $206M in EBITDA, and $96M in net income.

Revenue (LTM)


Embla Medical P&L

In the most recent fiscal year, Embla Medical reported revenue of $929M and EBITDA of $187M.

Embla Medical is profitable as of last fiscal year, with gross margin of 62%, EBITDA margin of 20%, and net margin of 9%.

See analyst estimates for Embla Medical
LTMLast FY202320242025202620272028
Revenue$1B$929M$786M$855M$929M
Gross Profit$625M$579M$486M$535M$579M
Gross Margin62%62%62%63%62%
EBITDA$206M$187M$140M$168M$187M
EBITDA Margin21%20%18%20%20%
EBIT Margin14%13%11%13%13%
Net Profit$96M$83M$58M$68M$83M
Net Margin10%9%7%8%9%
Net Debt-$286M---

Financial data powered by Morningstar, Inc.

Embla Medical Stock Performance

Embla Medical has current market cap of $1.7B, and enterprise value of $2.2B.

Market Cap Evolution


Embla Medical's stock price is $4.07.

Embla Medical share price decreased by 1.4% in the last 30 days, and by 21.6% in the last year.

Embla Medical has an EPS (earnings per share) of $0.20.

See more trading valuation data for Embla Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2.2B$1.7B0.5%-1.4%-6.6%-21.6%$0.20

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Embla Medical Valuation Multiples

Embla Medical trades at 2.2x EV/Revenue multiple, and 10.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Embla Medical

EV / Revenue (LTM)


Embla Medical Financial Valuation Multiples

As of October 14, 2026, Embla Medical has market cap of $1.7B and EV of $2.2B.

Embla Medical has a P/E ratio of 18.0x.

LTMLast FY202320242025202620272028
EV/Revenue2.2x2.3x2.8x2.5x2.3x
EV/EBITDA10.5x11.6x15.4x12.9x11.6x
EV/EBIT15.3x17.3x24.7x19.2x17.3x
EV/Gross Profit3.5x3.7x4.5x4.0x3.7x
P/E18.0x20.8x29.6x25.4x20.8x
EV/FCF25.2x21.6x41.6x28.1x21.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Embla Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Embla Medical Margins & Growth Rates

Embla Medical grew revenue by 10% and EBITDA by 13% in the last fiscal year.

In the most recent fiscal year, Embla Medical reported gross margin of 62%, EBITDA margin of 20%, and net margin of 9%.

See estimated margins and future growth rates for Embla Medical

Embla Medical Margins

Last FY202420252026202720282029
Gross Margin62%63%62%63%
EBITDA Margin20%20%20%21%
EBIT Margin13%13%13%14%
Net Margin9%8%9%10%
FCF Margin11%9%11%8%

Embla Medical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%9%9%10%
Gross Profit Growth10%10%8%10%
EBITDA Growth13%19%11%13%
EBIT Growth17%29%11%17%
Net Profit Growth19%17%22%19%
FCF Growth(18%)48%31%(18%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Embla Medical Operational KPIs

Embla Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Embla Medical's Rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Embla Medical's Rule of X is 45% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Embla Medical
LTMLast FY202320242025202620272028
Rule of 4028%30%---
Bessemer Rule of X40%45%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue36%36%37%36%36%
G&A Expenses to Revenue8%8%9%8%8%
R&D Expenses to Revenue5%5%5%5%5%
Opex to Revenue-49%51%49%49%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Embla Medical Competitors

Embla Medical competitors include Establishment Labs, 4DMedical, Poly Medicure, Insight Lifetech, Alphatec Holdings, Jafron Biomedical, NovoCure, Nihon Kohden, Edge Medical and Alamar Biosciences.

Most Embla Medical public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Establishment Labs$211M($23M)9.2x7.5x(85.1x)172.5x
4DMedical$5M($141M)314.2x188.0x(10.8x)(28.3x)
Poly Medicure$194M$58M8.5x7.4x28.6x30.3x
Insight Lifetech$81M$18M20.0x15.0x90.0x-
Alphatec Holdings$764M($15M)2.9x2.5x(146.2x)16.8x
Jafron Biomedical$301M$123M5.4x5.2x13.2x11.2x
NovoCure$655M($117M)2.2x2.1x(12.4x)427.8x
Nihon Kohden$1.5B$163M1.0x1.0x9.2x9.0x

This data is available for Pro users. Sign up to see all Embla Medical competitors and their valuation data.

Start Free Trial

Acquisitions by Embla Medical

Embla Medical has acquired 1 company to date.

Last acquisition by Embla Medical was on August 29th 2025. Embla Medical acquired Streifeneder for $26M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Embla Medical

Streifeneder
Description
Streifeneder is a German manufacturer of medical fixation and positioning devices based in Pegnitz, Bavaria. The company produces orthopedic splints, trauma care systems, and rehabilitation aids using thermoplastic materials. Its product portfolio includes the Streifeneder Fixateur for fracture immobilization and specialized supports for burns and neurology patients. Streifeneder supplies hospitals, clinics, and emergency services across Europe with customizable splinting solutions developed since 1950.
HQ CountryGermany
HQ City
Emmering
Deal Date29 Aug 2025
Valuation$26M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Embla Medical acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Embla Medical

When was Embla Medical founded?Embla Medical was founded in 1971.
Where is Embla Medical headquartered?Embla Medical is headquartered in Iceland.
How many employees does Embla Medical have?As of today, Embla Medical has over 4K employees.
Who is the CEO of Embla Medical?Embla Medical's CEO is Sveinn Solvason.
Is Embla Medical publicly listed?Yes, Embla Medical is a public company listed on Nasdaq Copenhagen.
What is the stock symbol of Embla Medical?Embla Medical trades under EMBLA ticker.
When did Embla Medical go public?Embla Medical went public in 2009.
Who are competitors of Embla Medical?Embla Medical main competitors include Establishment Labs, 4DMedical, Poly Medicure, Insight Lifetech, Alphatec Holdings, Jafron Biomedical, NovoCure, Nihon Kohden, Edge Medical, Alamar Biosciences.
What is the current market cap of Embla Medical?Embla Medical's current market cap is $1.7B.
What is the current revenue of Embla Medical?Embla Medical's last 12 months revenue is $1B.
What is the current revenue growth of Embla Medical?Embla Medical revenue growth (NTM/LTM) is 8%.
What is the current EV/Revenue multiple of Embla Medical?Current revenue multiple of Embla Medical is 2.2x.
What is the current EBITDA of Embla Medical?Embla Medical's last 12 months EBITDA is $206M.
What is Embla Medical's EBITDA margin?Embla Medical's last 12 months EBITDA margin is 21%.
What is the current EV/EBITDA multiple of Embla Medical?Current EBITDA multiple of Embla Medical is 10.5x.
What is the current FCF of Embla Medical?Embla Medical's last 12 months FCF is $86M.
What is Embla Medical's FCF margin?Embla Medical's last 12 months FCF margin is 9%.
What is the current EV/FCF multiple of Embla Medical?Current FCF multiple of Embla Medical is 25.2x.
How many companies Embla Medical has acquired to date?As of October 2026, Embla Medical has acquired 1 company.
What was the largest acquisition by Embla Medical?$26M acquisition of Streifeneder on 29th August 2025 was the largest M&A Embla Medical has done to date.
What companies Embla Medical acquired?Embla Medical acquired Streifeneder.
In how many companies Embla Medical has invested to date?Embla Medical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Embla Medical

Lists including Embla Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial